Description | G-418(disulfate)isanaminoglycosideantibioticsimilarinstructuretogentamicinB1,whichblockspolypeptidesynthesisbyinhibitingtheelongationstepinbothprokaryoticandeukaryoticcells. |
---|---|
InVitro | G418isaninhibitorofmanypro-andeukaryotesatconcentrationsfrom1-300microgram/mL.ResistancetoG418conferringbytheneogenefromTn5encodinganaminoglycoside3"-phosphotransferase,APT3"IIiscommonlyusedinlaboratoryresearchtoselectgeneticallyengineeredcells[1].Ingeneralforbacteriaandalgaeconcentrationsof5mg/Lorlessareused,formammaliancellsconcentrationsofapproximately400mg/Lareusedforselectionand200mg/Lformaintenance.Resistantclonesselectioncouldrequirefrom1toupto3weeks[2]. |
InVivo | G418(40and80mg/kg)forthreeconsecutivedaysaresufficienttoeliminateallnontransfectedT.bruceibruceiparasitesfrominfectedmice[3]. |
References |
|
AnimalAdmiNISTration [3] | TocharacterizethesensitivityofthetrypanosomepopulationstoG418invivo,bloodstreamformsofT.bruceibruceiGUTat3.1andT.bruceibruceiGUTat3.1/BBR3areexpandedseparatelyinsublethallyirrADIatedmice.Priortothefirstpeakofparasitemia,trypanosomesarecollected,andaliquotscontaining106trypanosomesareinoculatedintraperitoneallyintomice.Twenty-fourhoursfollowinginfection,themicearedividedintogroupsandtreatedwithG418atadoseof10,20,30,40,50,or80mg/kgofbodyweight(bw)byinoculatingintraperitoneally0.2mLofthedruginsterilewater.At24and48hfollowingthefirsttreatment,G418isadministeredtoanimalsineachgroupatthesamedoseasbefore,resultinginthreetreatmentspermouse.RepeateddrugtreatmentsarenecessarytoensurecompleteeliminationofnontransfectedGUTat3.1parasitesfromthemice.Micearethenmonitoreddaily,for33days,forthepresenceofparasitesbymicroscopicexaminationofwet-bloodfilms.Animalsfoundtobeparasitemicarerecordedandthenremovedfromtheexperiment.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. References |
|
---|